Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Ettore Bichisao"'
Autor:
Roberto Buzzoni, Laura Catena, Giuseppe Procopio, Ettore Bichisao, Sara De Dosso, Marco Platania, Alessandra Fabbri, Emilio Bajetta
Publikováno v:
Scopus-Elsevier
Skin cancers are the most common tumors in the transplant population. Merkel cell carcinoma (MCC) is a rare lesion in the general population, and only 52 cases have been reported in transplants recipients worldwide: 41 cases registered in the Cincinn
Autor:
Roberto Bajetta, Sara De Dosso, Elena Verzoni, Laura Catena, Giuseppe Procopio, Leonardo Ferrari, Emilio Bajetta, Antonia Martinetti, Ettore Bichisao, Barbara Formisano, Marco Platania
Publikováno v:
Cancer Chemotherapy and Pharmacology. 59:637-642
The aim of this trial was to evaluate the safety and efficacy of oxaliplatin and capecitabine (XELOX) in neuroendocrine tumours’ (NETs) treatment. Forty patients (pts) with advanced NETs were treated. Of these, 13 had untreated poorly differentiate
Autor:
J. Rosai, Stefano Iacobelli, Ettore Bichisao, Roberto Buzzoni, S De Dosso, Luigi Mariani, S. Della Torre, Emilio Bajetta, G. Procopio, Laura Catena, Leonardo Ferrari
Publikováno v:
Annals of Oncology. 16:1374-1380
Background: Neuroendocrine tumours (NETs) are a rare and heterogeneous group of neoplasms. The most recent WHO classification provides clinical tools and indications to make the diagnosis and to suggest the correct treatment in different subgroups of
Autor:
D. De Candis, Ettore Seregni, R. Miceli, Emilio Bombardieri, Luigi Mariani, I. La Torre, P. Pozzi, Nicoletta Zilembo, Leonardo Ferrari, V.R. Longarini, Emilio Bajetta, A. Martinetti, Ettore Bichisao
Publikováno v:
The Breast. 11:286-294
To investigate whether c-erbB 2 serum levels may be predictive of clinical response, progression-free and overall survival in postmenopausal women with advanced breast cancer hormonally treated, 265 patients enrolled in previous clinical trials were
Publikováno v:
Critical Reviews in Oncology/Hematology. 33:137-142
The choice of treatment for elderly breast cancer patients needs particular care because the presence of physiological functional impairments can modify the drug bioavailability in an unpredictable manner. Hormonal treatment remains one of the choice
Autor:
Mitchell Dowsett, A. Marchianò, Luigi Celio, S Stani, P. Pozzi, Emilio Bajetta, Antonia Martinetti, L Guillevin, Nicoletta Zilembo, A. Di Leo, Ettore Bichisao
Publikováno v:
European Journal of Cancer. 35:208-213
Letrozole is an orally competitive aromatase inhibitor. This double-blind, randomised, multicentre trial was carried out to evaluate the endocrine effects of two doses of letrozole, 0.5 mg versus 2.5 mg orally daily, in postmenopausal advanced breast
Autor:
A. Martinetti, G. Commella, M. D'Aprile, Cristina Noberasco, A. Attili, Sandro Barni, Roberto Buzzoni, Emilio Bajetta, Leonardo Ferrari, Nicoletta Zilembo, Giuseppe Schieppati, A. Jirillo, G. F. Bolelli, M. Amichetti, Ettore Bichisao, Emilio Bombardieri
Publikováno v:
Annals of Oncology. 8:649-654
Summary Background In postmenopausal breast cancer (BC) patients, tamoxifen (TAM) is frequently used in first-line therapy, and for those relapsing under TAM, aromatase inhibitors would be the drug of choice. Formestane, a new aromatase inhibitor, ha
Autor:
Ettore Bichisao, Elisabetta Sansoni, Romina Agostinelli, Giuseppina Catalano, Vincenzo Catalano, Stefano Cascinu, Paolo Giordani, Dino Amadori, Vittorio Silingardi, Gabriele Luppi
Publikováno v:
Scopus-Elsevier
Thirty-seven colorectal cancer patients with grade 1-4 diarrhea (NCICTC) caused by chemotherapy with 5-FU-containing regimens, received oral loperamide at the initial dose of 4 mg followed by 4 mg every 8 h (total dose 16 mg/24 h). Twenty-five patien
Autor:
Laura, Ridolfi, Giammaria, Fiorentini, Michele, Guida, Maria, Michiara, Andrea, Freschi, Enrico, Aitini, Michela, Ballardini, Ettore, Bichisao, Ruggero, Ridolfi, E T, Menichetti
Publikováno v:
Melanoma research. 19(2)
The efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 biochemotherapy were evaluated in advanced melanoma patients. The schedule consisted of fotemustine (100 mg/m) and cisplatin (75 mg/m) intravenous on day 1, f
Autor:
Carlo Maurizio Camaggi, Andrea Martoni, Elena Strocchi, S. Miseria, G. Robustelli Della Cuna, M. Balli, Ettore Bichisao, G. Bonciarelli, G. Ambroso, P. Malacarne, M. Indelli, Franco Pannuti, R. Cellerino
Publikováno v:
Cancer Chemotherapy and Pharmacology. 27:451-455
Drug plasma levels, metabolism data and clinical results were evaluated after the daily administration of either 500 or 1,000 mg aminoglutethimide (AG, Orimeten, Ciba-Geigy) plus hydrocortisone acetate (20 mg b. i. d.). A total of 34 patients with ad